BIO-Europe® 2016: F-star business chief discuss Denali deal and potential F-star delta spinout

November 22, 2016
Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star's asset-centric business strategy, the company's recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.
Previous Video
BIO-Europe® 2016: Karus CEO highlights niche indications for oncology innovation
BIO-Europe® 2016: Karus CEO highlights niche indications for oncology innovation

Karus Therapeutics CEO, Simon Kerry, talks to Scrip senior writer, Lucie Ellis, during the recent BIO-Europ...

Next Video
BIO-Europe® 2016: Freshly-appointed Auspherix CEO highlights new antibiotic class
BIO-Europe® 2016: Freshly-appointed Auspherix CEO highlights new antibiotic class

Dr. Neil Miller, the recently-appointed CEO of UK-based biotech, Auspherix, talks to Scrip about the compan...